Pharmaceuticals & Therapeutics

InterAx's AI platform and Alveus's R&D expertise combine in a new partnership to develop a next-gen obesity drug with durable results and better tolerability.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

With its lead cancer therapy pelareorep showing promise, Oncolytics hires veteran execs to navigate the final hurdles of clinical trials and regulatory approval.

A novel biologic therapy from Immunis shows significant gains in walking speed for obese seniors, hinting at a new frontier in treating age-related decline.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

A new partnership reveals how integrating mental health is revolutionizing oncology, improving patient outcomes, and setting a new standard for whole-person care.

A revolutionary bone graft that accelerates healing is now approved for more spinal surgeries, offering new hope to patients with chronic back pain.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

As a foundational CFO steps down, XOMA Royalty brings in biotech veteran Jeffrey Trigilio to enhance its dealmaking strategy and expand its royalty portfolio.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.